Patents by Inventor Lajos Tarcsay
Lajos Tarcsay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5821336Abstract: The invention concerns polypeptides with an apparent molecular weight of around 160 kD which are mediators or precursors for mediators of inflammation, derivatives thereof such as mutants and fragments, processes for their preparation, DNAs and hybrid vectors coding for the polypeptides and derivatives and host cells transformed with such hybrid vectors, polyclonal and monoclonal antibodies specific for the polypeptides or their derivatives and antibody derivatives as well as diagnostic and therapeutic methods for inflammatory conditions and Hodgkin lymphomas.Type: GrantFiled: September 27, 1996Date of Patent: October 13, 1998Assignee: Novartis CoporationInventors: Karel Gerrit Odink, Lajos Tarcsay, Josef Bruggen, Walter Wiesendanger, Nico Cerletti, Clemens Sorg, Christiane DeWolf-Peeters, Jan Delabie
-
Patent number: 5702920Abstract: The invention concerns polypeptides related to human macrophage migration inhibition factor, in particular the polypeptides called MRP-8 and MRP-14, processes for their preparation, mRNAs, DNAs and hybrid vectors coding for those polypeptides, hosts transformed with such a hybrid vector, monoclonal and polyclonal antibodies to those polypeptides, and diagnostic methods for inflammatory conditions and cystic fibrosis.Type: GrantFiled: July 27, 1995Date of Patent: December 30, 1997Assignee: Novartis CorporationInventors: Karel Gerrit Odink, Roger Clerc, Nico Cerletti, Josef Bruggen, Lajos Tarcsay, Clemens Sorg, Walter Wiesendanger
-
Patent number: 5411882Abstract: The invention concerns polypeptides with an apparent molecular weight of around 160 kD which are mediators or precursors for mediators of inflammation, derivatives thereof such as mutants and fragments, processes for their preparation, DNAs and hybrid vectors coding for said polypeptides and derivatives and host cells transformed with such hybrid vectors, polyclonal and monoclonal antibodies specific for said polypeptides or their derivatives and antibody derivatives as well as diagnostic and therapeutic methods for inflammatory conditions and Hodgkin lymphomas.Type: GrantFiled: December 20, 1991Date of Patent: May 2, 1995Assignee: Ciba-Geigy CorporationInventors: Karel G. Odink, Lajos Tarcsay, Josef Bruggen, Walter Wiesendanger, Nico Cerletti, Clemens Sorg, Christiane DeWolf-Peeters, Jan Delabie
-
Patent number: 5350687Abstract: The invention concerns polypeptides related to human macrophage migration inhibition factor, in particular the polypeptides called MRP-8 and MRP-14, processes for their preparation, mRNAs, DNAs and hybrid vectors coding for said polypeptides, hosts transformed with such a hybrid vector, monoclonal and polyclonal antibodies to said polypeptides , and diagnostic methods for inflammatory conditions and cystic fibrosis.Type: GrantFiled: November 21, 1990Date of Patent: September 27, 1994Assignee: Ciba-Geigy CorporationInventors: Karel G. Odink, Roger Clerc, Nico Cerletti, Josef Bruggen, Lajos Tarcsay, Clemens Sorg, Walter Wiesendanger
-
Patent number: 4971802Abstract: The invention relates to pharmaceutical compositions containing synthetic, substantially pure phosphatidyl serine and phosphatidyl choline and a substance or a mixture of substances having biological activity. The invention also relates to mixtures comprising synthetic, substantially pure phosphatidyl serine and phosphatidyl choline, and also to processes for the manufacture of the pharmaecutical compositions, and the use thereof.Type: GrantFiled: August 16, 1989Date of Patent: November 20, 1990Assignee: Ciba-Geigy CorporationInventors: Lajos Tarcsay, Hansjorg Eibl, Peter Fankhauser, Anita Peil
-
Patent number: 4574058Abstract: The invention relates to novel antigen derivatives comprising an antigen and at least one muramylpeptide covalently bonded thereto, if appropriate via a spacer, to pharmaceutical preparations which contain such compounds and to their use as a vaccine.The novel antigen derivatives produce a pronounced increase in the immuno-response to the antigen, and in particular also a cell-medicated immunity under clinically acceptable conditions of administration.Type: GrantFiled: March 21, 1983Date of Patent: March 4, 1986Assignee: Ciba-Geigy CorporationInventors: Gerhard Baschang, Felix M. Dietrich, Roland Gisler, Albert Hartmann, Jaroslav Stanek, Lajos Tarcsay
-
Patent number: 4548923Abstract: The compounds of the formula I ##STR1## in which each of R.sup.1, R.sup.4 and R.sup.6, independently of the others, represents hydrogen or lower alkanoyl, R.sup.2 represents C.sub.1-4 -alkyl, hydroxymethyl or phenyl, R.sup.3 represents hydrogen or methyl, R.sup.5 represents hydrogen or C.sub.1-3 -alkyl, R.sup.7 represents C.sub.1-3 -alkyl that is unsubstituted or substituted by hydroxy, mercapto or methylthio, R.sup.8 represents hydrogen or lower alkyl, X represents oxygen or the group NH, Y represents C.sub.1-4 -alkylidene, and each of R.sup.9 and R.sup.10, independently of the other, represents C.sub.11-17 -alkyl or C.sub.11-17 -alkenyl, and their salts, have an immunostimulating activeity.Type: GrantFiled: May 9, 1984Date of Patent: October 22, 1985Assignee: Ciba Geigy CorporationInventors: Albert Hartmann, Oskar Wacker, Gerhard Baschang, Lajos Tarcsay
-
Patent number: 4446128Abstract: The invention relates to novel antigen derivatives comprising an antigen and at least one muramyl-peptide covalently bonded thereto, if appropriate via a spacer, to pharmaceutical preparations which contain such compounds and to their use as a vaccine.The novel antigen derivatives produce a pronounced increase in the immuno-response to the antigen, and in particular also a cell-medicated immunity under clinically acceptable conditions of administration.Type: GrantFiled: May 18, 1982Date of Patent: May 1, 1984Assignee: Ciba-Geigy CorporationInventors: Gerhard Baschang, Felix M. Dietrich, Roland Gisler, Albert Hartmann, Jaroslav Stanek, Lajos Tarcsay
-
Patent number: 4439425Abstract: The present invention relates to new lipopeptides and in particular to compounds of either of the formulae ##STR1## wherein R.sub.1 and R.sub.2 each represent a saturated or unsaturated aliphatic or mixed aliphatic-cycloaliphatic hydrocarbon radical which has 11-21 C atoms and which is also optionally substituted by oxygen functions, R.sub.3 represents hydrogen or the radical R.sub.1 --CO--O--CH.sub.2 --, where R.sub.1 has the same meaning, R.sub.1 ' is a saturated or unsaturated aliphatic hydrocarbon radical of at least 9 C atoms, which is optionally substituted at one of the C atoms non adjacent to the sulfur atom by a free hydroxyl group or a hydroxyl group esterified with a monobasic carboxylic acid and which is optionally interrupted in the C atoms chain by one or more oxygen atoms, and which hydrocarbon is optionally substituted by a maximum of 2 cycloaliphatic hydrocarbon radicals having 5-8 ring C atoms, or R.sub.1 ' is the radical --CO--R.sub.1 ", wherein R.sub.Type: GrantFiled: June 7, 1982Date of Patent: March 27, 1984Assignee: Ciba-Geigy CorporationInventors: Lajos Tarcsay, Bruno Kamber, Jaroslav Stanek, Gerhard Baschang, Albert Hartmann
-
Patent number: 4423038Abstract: There are described hexopyranose compounds of the formula I and salts thereof having immunomodulatory action, which can be used, for example, in the form of pharmaceutical preparations, and also together with antibiotics, and processes for their manufacture. ##STR1## The variables are as described in the disclosure. The invention relates to the above-mentioned compounds as immunomodulators, especially as immunostimulants, their use as pharmacologically active substances, especially their use as immunomodulators, particularly as immunostimulants, and their use for the manufacture of pharmaceutical preparations, and to pharmaceutical preparations containing these compounds.Type: GrantFiled: January 19, 1982Date of Patent: December 27, 1983Assignee: Ciba-Geigy CorporationInventors: Gerhard Baschang, Albert Hartmann, Oskar Wacker, Lajos Tarcsay
-
Patent number: 4414204Abstract: The invention relates to pharmaceutical preparations that contain an antibiotic and a muramylpeptide of the formula I or a salt thereof, to processes for their manufacture and to a method for increasing the antibiotic effectiveness of antibiotics. ##STR1## In the formula I, X represents carbonyl or carbonyloxy, R.sub.1 represents optionally substituted alkyl or aryl, R.sub.2, R.sub.3, R.sub.4 and R.sub.6 represent hydrogen or lower alkyl, R.sub.5 represents hydrogen, optionally substituted lower alkyl, cycloalkyl, aryl or nitrogen-containing heterocyclyl, or R.sub.4 and R.sub.5 together represent also C.sub.3 -C.sub.4 alkylene, R.sub.7 represents hydrogen or free, esterified or amidated carboxyl, one of the radicals A.sub.1 and A.sub.2 represents a radical of the formula II and the other of the radicals A.sub.1 and A.sub.2 represents optionally substituted or functionally modified hydroxy or amino.Type: GrantFiled: January 21, 1981Date of Patent: November 8, 1983Assignee: Ciba-Geigy CorporationInventors: Lajos Tarcsay, Gerhard Baschang, Albert Hartmann, Jaroslav Stanek
-
Patent number: 4409209Abstract: Phosphorylmuramyl peptides of the formula ##STR1## are immuno-potentiating. In the formula, R.sub.1 represents optionally substituted alkyl or aryl, R.sub.2, R.sub.4, R.sub.6 and R.sub.7 represent, for example, hydrogen, R.sub.3 represents hydrogen or lower alkyl, R.sub.5 represents, for example, hydrogen, lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl or aralkyl, or nitrogen-containing heterocyclyl or heterocyclyl-lower alkyl, and one of the radicals A.sub.1 and A.sub.2 represents a radical of the formula (II) ##STR2## In the formula (II), T represents NH or O, Y represents an optionally substituted alkylene group, which may also be interrupted by one or two oxycarbonyl and/or iminocarbonyl groups, and W represents an aliphatic radical or a cycloalkyl or cycloalkenyl radical having more than 6 carbon atoms. The other of the radicals A.sub.1 and A.sub.2 represents free or etherified hydroxy, amino, lower alkylamino or aminocarbonyl-lower alkylamino.Type: GrantFiled: December 4, 1981Date of Patent: October 11, 1983Assignee: Ciba-Geigy CorporationInventors: Gerhard Baschang, Lajos Tarcsay, Albert Hartmann, Jaroslav Stanek
-
Patent number: 4406890Abstract: The invention relates to muramyl peptide compounds, especially of the formula ##STR1## in which R.sub.1 represents, for example, alkyl or phenyl,R.sub.3 represents, for example, hydrogen or methyl andR.sub.5 represents, for example, hydrogen or lower alkyl optionally substituted, for example, by hydroxy, mercapto, or methylthio,and in which one of the radicalsA.sub.1 and A.sub.2 represents a group of the formula ##STR2## in which T represents the group of the formula -NH or -O, andY represents an alkylene radical optionally interrupted by a radical of the formula -CO-O- or -CO-NH-,and in whichW represents hydrogen andZ represents a hydroxy-substituted ethyl group, wherein at least one hydroxy group is esterified by a long-chained acyl radical orW and Z represent hydroxymethyl, wherein hydroxy is esterified by a long-chained acyl radical,and the other of the radicals A.sub.1 and A.sub.2 represents optionally etherified hydroxy or optionally substituted amino.Type: GrantFiled: July 16, 1981Date of Patent: September 27, 1983Assignee: Ciba-Geigy CorporationInventors: Lajos Tarcsay, Gerhard Baschang, Albert Hartmann, Jaroslav Stanek
-
Patent number: 4397844Abstract: The invention relates to novel antigen derivatives comprising an antigen and at least one muramylpeptide covalently bonded thereto, if appropriate via a spacer, to pharmaceutical preparations which contain such compounds and to their use as a vaccine.The novel antigen derivatives produce a pronounced increase in the immuno-response to the antigen, and in particular also a cell-medicated immunity under clinically acceptable conditions of administration.Type: GrantFiled: September 17, 1981Date of Patent: August 9, 1983Assignee: Ciba-Geigy CorporationInventors: Gerhard Baschang, Felix M. Dietrich, Roland Gisler, Albert Hartmann, Jaroslav Stanek, Lajos Tarcsay
-
Patent number: 4323560Abstract: Phosphorylmuramyl peptides of the formula ##STR1## are immuno-potentiating. In the formula, R.sub.1 represents optionally substituted alkyl or aryl, R.sub.2, R.sub.4, R.sub.6 and R.sub.7 represent, for example, hydrogen, R.sub.3 represents hydrogen or lower alkyl, R.sub.5 represents, for example, hydrogen, lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl or aralkyl, or nitrogen-containing heterocyclyl or heterocyclyl-lower alkyl, and one of the radicals A.sub.1 and A.sub.2 represents a radical of the formula (II) ##STR2## In the formula (II), T represents NH or O, Y represents an optionally substituted alkylene group, which may also be interrupted by one or two oxycarbonyl and/or iminocarbonyl groups, and W represents an aliphatic radical or a cycloalkyl or cycloalkenyl radical having more than 6 carbon atoms. The other of the radicals A.sub.1 and A.sub.2 represents free or etherified hydroxy, amino, lower alkylamino or aminocarbonyl-lower alkylamino.Type: GrantFiled: October 6, 1980Date of Patent: April 6, 1982Assignee: Ciba-Geigy CorporationInventors: Gerhard Baschang, Lajos Tarcsay, Albert Hartmann, Jaroslav Stanek